Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study

Abstract

In patients with advanced melanoma in the CheckMate 066 study, baseline health-related quality of life (HRQoL) with nivolumab was maintained over time, with statistically significant and clinically meaningful improvements in some exploratory analyses, and no HRQoL improvements with dacarbazine. Added to the survival benefit of nivolumab, the benefit-to-risk ratio favors nivolumab over dacarbazine.

Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis

“…Patients treated with pembrolizumab had consistently smaller decrements in the symptoms scales for fatigue, nausea, anorexia, diarrhea, and constipation. Recently, Long et al reported PRO outcomes in the trial of nivolumab versus dacarbazine in patients with advanced melanoma . The EORTC QLQ‐C30 was evaluated at baseline and every 6 weeks while on treatment.…”

Mental Health Services Use by Melanoma Patients Receiving Adjuvant Interferon: Association of Pre-treatment Mental Health Care with Early Discontinuation

“…Patient-reported outcomes in a trial comparing placebo with high-dose adjuvant ipilimumab suggest a lesser, more transient effect on neurocognitive function 23 . Results from the use of anti-PD-1 agents in the metastatic setting suggest a favourable effect on quality of life 24,25 . Serious mental health or constitutional symptoms directly attributable to treatment appear to be rare 26,27 .…”

Highlights of the season 2016–2017 by the Spanish Melanoma Group (GEM)

“…Quality of life for nivolumab has been assessed in the Checkmate 066 study comparing nivolumab and chemotherapy at first line setting. Patients on nivolumab maintained baseline quality of life as measured by the Euroquality of Life Five Dimensions for longer time and did not show increased symptom burden as assessed by the QLQ-C30 (15).…”